Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

AKUS
Akouos, Inc. Common Stock
stock NASDAQ

Inactive
Nov 30, 2022
13.29USD+1.065%(+0.14)1,790,496
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-13.15)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
07:00AM EST  Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February:   GlobeNewswire Inc
Jan 7, 2022
07:00AM EST  Akouos to Present at the Association for Research in   GlobeNewswire Inc
Nov 22, 2021
07:00AM EST  Akouos to Present at Piper Sandler 33rd Annual Virtual Healthcare   GlobeNewswire Inc
Nov 12, 2021
07:26AM EST  Akouos Q3 EPS $(0.67) Up From $(0.85) YoY   Benzinga
07:00AM EST  - Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022   GlobeNewswire Inc
Nov 8, 2021
10:00AM EST  A Look Into Healthcare Sector Value Stocks   Benzinga
Nov 1, 2021
07:18AM EDT  Akouos Appoints Stacy Price As Chief Technical Officer   RTTNews
07:05AM EDT  Akouos Announces Stacy Price CTO   Benzinga
07:00AM EDT  Akouos Appoints Stacy Price as Chief Technical Officer   GlobeNewswire Inc
Oct 20, 2021
07:16AM EDT  Akouos To Present At Jefferies Gene Therapy/Editing Summit   Benzinga
Sep 27, 2021
10:20AM EDT  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Sep 20, 2021
10:44AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
Sep 7, 2021
07:00AM EDT  Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in September:   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 12, 2021
07:17AM EDT  Akouos Q2 EPS $(0.66) Up From $(11.14) YoY   Benzinga
07:00AM EDT  - Announced European Commission designation of AK-OTOF as an orphan drug for the treatment of otoferlin gene-mediated hearing loss   GlobeNewswire Inc
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
07:25AM EDT  Akouos Announces European Commission Designation Of AK-OTOF For Otoferlin Gene-Mediated Hearing Loss As An Orphan Drug   RTTNews
07:03AM EDT  Akouos Announces European Commission Designation Of AK-OTOF For Treatment oOf Otoferlin Gene-Mediated Hearing Loss As An Orphan Drug   Benzinga
07:00AM EDT  Akouos Announces European Commission Designation of AK-OTOF for   GlobeNewswire Inc
Aug 4, 2021
07:00AM EDT  Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in August:   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
07:18AM EDT  Akouos Q1 EPS $(0.47)   Benzinga
07:00AM EDT  - Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer   GlobeNewswire Inc
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
08:25AM EDT  Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF And AK-antiVEGF At American Society Of Gene And Cell Therapy 24th Annual Meeting   Benzinga
08:25AM EDT  - Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice   GlobeNewswire Inc
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
07:00AM EDT  Akouos Appoints Dr. Kathy Reape as Chief Development Officer   GlobeNewswire Inc
07:00AM EDT  Akouos to Present at Bank of America 2021 Virtual Healthcare   GlobeNewswire Inc
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
Apr 27, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2021   Benzinga
06:30AM EDT  HC Wainwright & Co. Initiates Coverage On Akouos with Buy Rating, Announces Price Target of $25   Benzinga
Apr 13, 2021
08:31AM EDT  Akouos Receives FDA Orphan Drug And Rare Pediatric Disease Designations For AK-OTOF For The Treatment Of Otoferlin Gene-Mediated Hearing Loss   Benzinga
08:30AM EDT  Akouos Receives Orphan Drug and Rare Pediatric Disease   GlobeNewswire Inc
Apr 8, 2021
07:00AM EDT  Akouos to Present at 20th Annual Needham Virtual Healthcare Conference   GlobeNewswire Inc
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 30, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2021   Benzinga
07:40AM EDT  B of A Securities Downgrades Akouos to Neutral, Lowers Price Target to $20   Benzinga
Mar 29, 2021
06:59AM EDT  Akouos Q4 EPS $(0.37) Up From $(14.31) YoY   Benzinga
06:58AM EDT  - In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF   GlobeNewswire Inc
Jan 29, 2021
07:45AM EST  The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO   Benzinga
Jan 28, 2021
08:03AM EST  The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO   Benzinga
Jan 11, 2021
07:00AM EST  Akouos and Blueprint Genetics Announce the Resonate Program to   GlobeNewswire Inc
Dec 22, 2020
06:25AM EST  The lockup period of Akouos Inc. (AKUS) expires tomorrow, i.e. on Dec. 23.   RTTNews
Nov 23, 2020
09:00AM EST  Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare   GlobeNewswire Inc
Nov 12, 2020
07:07AM EST  Akouos Q3 EPS $(0.85) Misses $(0.39) Estimate   Benzinga
07:00AM EST  - Expanded leadership team with appointment of Sachiyo Minegishi as CFO and promotion of Jennifer Wellman to COO -   GlobeNewswire Inc
Oct 1, 2020
07:00AM EDT  Akouos Announces Key Leadership Appointments   GlobeNewswire Inc
Sep 24, 2020
08:00AM EDT  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will present at two upcoming virtual investor conferences in October:   GlobeNewswire Inc
Sep 8, 2020
08:00AM EDT  Akouos to Present at Cantor Global Virtual Healthcare Conference   GlobeNewswire Inc
Aug 13, 2020
07:11AM EDT  Akouos Q2 EPS $(11.14) Down From $(3.42) YoY   Benzinga
07:00AM EDT  Akouos Reports Second Quarter 2020 Financial Results and Provides   GlobeNewswire Inc
Aug 5, 2020
08:00AM EDT  Akouos Announces Expansion of Executive Team and Board of Directors   GlobeNewswire Inc
Aug 3, 2020
08:00AM EDT  Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live with disabling hearing loss, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10 at 10:30 a.m. ET.   GlobeNewswire Inc
Jul 21, 2020
09:37AM EDT  Benzinga's Top Upgrades, Downgrades For July 21, 2020   Benzinga
08:08AM EDT  B of A Securities Initiates Coverage On Akouos with Buy Rating, Announces Price Target of $24   Benzinga
08:07AM EDT  Cowen & Co. Initiates Coverage On Akouos with Outperform Rating   Benzinga
05:38AM EDT  Piper Sandler Initiates Coverage On Akouos with Overweight Rating, Announces Price Target of $40   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC